Affordability and Sustainability improvements by using new pricing, Cost-Effectiveness and ReimbursemenT models to Appraise iNnovative health technologies

Project Information

ASCERTAIN

Grant agreement ID: 101094938

DOI

10.3030/101094938

EC signature date 24 November 2022

Start date 1 December 2022

End date 30 November 2026

Funded under

• Health

Total cost

€ 4 966 716,00

EU contribution

€ 4 966 716,00

Coordinated by

ERASMUS UNIVERSITEIT ROTTERDAM
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (3)

Analysis on literature reviews of state-of-the-art.

Report analyzes elements of cost-based and value-based pricing policies, HTA frameworks, thresholds, reimbursement models and payment schemes.

Dissemination, exploitation, and communication plan

This document will set out the principles and main strategies to guide dissemination, exploitation and communication during the project peroid. The plan will be complemented by yearly action plans that specify expected tasks, targets and deadlines.

Project and data management handbook

All relevant project related information for the consortium will be collected in project handbook. It includes general information of agreements, project organizational structure, communication and dissemination practices, internal review, process of deliverables and payments, for example.

Websites, patent fillings, videos etc. (1)

Project website

The project website will be the principle instrument for communication on the project´s objectives and achievements. All partners will be consulted with proposals for the look-and-feel and the structure of the website. During the project period, all partners will contribute with information to population the project website.

Publications

Peer reviewed articles (5)

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

Author(s): R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
Published in: PLOS ONE, Issue 19, 2024, ISSN 1932-6203
Publisher: Public Library of Science (PLoS)
DOI: 10.1371/JOURNAL.PONE.0293264

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review

Author(s): Nicolas S. H. Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski, Frederick W. Thielen, Carin A. Uyl-de Groot
Published in: The European Journal of Health Economics, 2025, ISSN 1618-7598
Publisher: Springer Science and Business Media LLC
DOI: 10.1007/S10198-025-01834-Y

Microcosting Study of Genomic Profiling for Precision Cancer Medicine

Author(s): Pia S. Henkel, Eline Aas, Hege G. Russnes, Ingrid Dyvik, G. Live Fagereng, Åslaug Helland, Hanna Røgenes, Tonje G. Lien, Kine Pedersen
Published in: The Journal of Molecular Diagnostics, Issue 27, 2025, ISSN 1525-1578
Publisher: Elsevier BV
DOI: 10.1016/J.JMOLDX.2025.06.006

Bridging Affordability and Sustainability of Health Innovations via Novel Pricing, Cost-effectiveness, and Reimbursement Models to Improve Patient Access: The ASCERTAIN Project

Author(s): Carin A. Uyl-de Groot, Nicolas S.H. Xander, Tom Belleman, Emily A. Burger, Robin Doeswijk, Isabelle Durand-Zaleski, Benjamin P. Geisler, Oliver Groene, Anne Hendrickx, Pia S. Henkel, Renaud Heine, Mirjana Huić, Mauro Melli, Kate Morgan, Monica Racovița, Gauthier Quinonez, Maureen P.M.H. Rutten-van Mölken, Tomáš Tesař, Frederick W. Thielen, Peter Schneider, Yansi Wu, Maximilian Salcher-Konrad, Eline Aas
Published in: Health Policy and Technology, 2026, ISSN 2211-8837
Publisher: Elsevier BV
DOI: 10.1016/J.HLPT.2026.101155

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Author(s): Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot
Published in: Value in Health, Issue 27, 2025, ISSN 1098-3015
Publisher: Elsevier BV
DOI: 10.1016/J.JVAL.2024.06.003